Anteris Technologies Limited news
- Anteris Technologies (AVR) pauses trading as it plans for an upcoming capital raise
- On Thursday, the company entered a trading halt, pausing shares until Monday, August 2
- It is unknown how much the company is planning to raise or where the funds will be spent
- On the market, Anteris last traded at $8.59 per share
On Thursday, the company e
Anteris Technologies` Wayne Paterson provides an overview of a proposal that`s landed on the company`s desk, which asks it to consider a merger with NASDAQ-listed special purpose acquisition company Medicus Sciences Acquisition Corp. It`s still early days for the proposal, but if a transaction goes through, the merged entity would have at least US$50 million in cash, plus the existing funds held by the company. Moving ahead, AVR plans to do the math and weigh up the proposal`s r
Anteris Technologies Ltd (ASX: AVR) reports the first-in-human DurAVR™ THV study met or exceeded its interim study objectives.
At the 30-day follow up point, the first five patients of the planned 10-patient study showed:
- All five subjects continued to do well with no reported adverse events (no death, stroke, myocardial infarction, reintervention).
- An average 86% improvement in mean gradient (standard measure of stenosis severity) from pre-treatment lev
Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF)`s Wayne Paterson tells Proactive about the 30-day follow-up data just in from the company’s flagship heart valve, currently being tested in humans for the first time. The valve solves the problem of younger and more active heart patients who need a valve that performs better and lasts longer, and Paterson says these latest clinical results meet and exceed the company’s expectations.
Anteris reports successfully implanting five TAVR patients during the week of 14 November 2021 in a first-in-human (FIH) study to assess the DurAVR THV system for treating severe aortic stenosis. The study was carried out at the Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia.
The transcatheter aortic valve replacement procedures for all five patients were successful and without any complications. An additional five patients are planned for treatment in the first quarter of 2022 t